Eli Lilly wants to gain on Novo Nordisk's obesity lead

US-based Eli Lilly has recently released strong data for its obesity drug, and is now investigating options to get it onto the market sooner than expected.
Photo: Mike Blake/Reuters/Ritzau Scanpix
Photo: Mike Blake/Reuters/Ritzau Scanpix
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen

While Novo Nordisk has taken the center stage of the obesity market in the US, the Danish pharmaceutical firm’s archrival there, Eli Lilly, is plotting ways to commercially challenge Wegovy with its own candidate, tirzepatide.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading